Drugs by condition
Drugs approved for acne
Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
45
Still marketed, NDA or BLA
Drug classes
7
Novel drugs
6
New molecular entities and new biologics
In development
6
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for acne.
- Cabtreo (Adapalene, Benzoyl Peroxide, Clindamycin Phosphate) · Bausch Oct 20, 2023
- Twyneo (Benzoyl Peroxide, Tretinoin) · Mayne Pharma Jul 26, 2021
- Winlevi (Clascoterone) · Sun Pharm NovelAug 26, 2020
- Arazlo (Tazarotene) · Bausch Dec 18, 2019
- Absorica Ld (Isotretinoin) · Sun Pharm Nov 5, 2019
All approved drugs for acne, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 219 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Retinoid (22)
- Aklief Trifarotene · Galderma Labs Lp · 2019
- Tazorac Tazarotene · Chartwell Rx · 1997
- Cabtreo Adapalene, Benzoyl Peroxide, Clindamycin Phosphate · Bausch · 2023
- Twyneo Benzoyl Peroxide, Tretinoin · Mayne Pharma · 2021
- Arazlo Tazarotene · Bausch · 2019
- Absorica Ld Isotretinoin · Sun Pharm · 2019
- Altreno Tretinoin · Dow Pharm · 2018
- Epiduo Forte Adapalene, Benzoyl Peroxide · Galderma Labs · 2015
- Absorica Isotretinoin · Sun Pharm Inds INC · 2012
- Fabior Tazarotene · Mayne Pharma · 2012
- Atralin Tretinoin · Dow Pharm · 2007
- Differin Adapalene · Galderma Labs Lp · 2007
- Ziana Clindamycin Phosphate, Tretinoin · Bausch · 2006
- Tazorac Tazarotene · Chartwell Rx · 2000
- Differin Adapalene · Galderma Labs Lp · 2000
- Retin-A-Micro Tretinoin · Bausch · 1997
- Avita Tretinoin · Mylan Pharms INC · 1997
- Retin-A Tretinoin · Bausch · 1988
- Retin-A Tretinoin · Bausch · 1978
- Retin-A Tretinoin · Valeant Intl · 1975
- Retin-A Tretinoin · Bausch · 1974
- Retin-A Tretinoin · Bausch · 1973
Sulfone (2)
Androgen Receptor Inhibitor (1)
- Winlevi Clascoterone · Sun Pharm · 2020
Aminoglycoside Antibacterial (1)
- Zylet Loteprednol Etabonate, Tobramycin · Bausch and Lomb · 2004
Tetracycline-class Drug (1)
- Monodox Doxycycline · Chartwell Rx · 1989
Corticosteroid (1)
- Maxidex Dexamethasone · Harrow Eye · 1962
Class not listed in FDA's data (17)
- Seysara Sarecycline Hydrochloride · Almirall · 2018
- Lotemax Loteprednol Etabonate · Bausch and Lomb · 1998
- Azelex Azelaic Acid · Almirall · 1995
- Amzeeq Minocycline Hydrochloride · Journey · 2019
- Acticlate Doxycycline Hyclate · Chartwell Rx · 2014
- Beyaz Drospirenone, Ethinyl Estradiol, Levomefolate Calcium · Bayer Hlthcare · 2010
- Acanya Benzoyl Peroxide, Clindamycin Phosphate · Bausch · 2008
- Yaz Drospirenone, Ethinyl Estradiol · Bayer Hlthcare · 2006
- Doryx Mpc Doxycycline Hyclate · Mayne Pharma · 2005
- Clindagel Clindamycin Phosphate · Bausch · 2000
- Klaron Sulfacetamide Sodium · Bausch · 1996
- Cleocin T Clindamycin Phosphate · Pfizer · 1989
- Cleocin T Clindamycin Phosphate · Pfizer · 1987
- Benzamycin Benzoyl Peroxide, Erythromycin · Valeant Intl · 1984
- Omnipred Prednisolone Acetate · Sandoz · 1973
- Minocin Minocycline Hydrochloride · Rempex · 1972
- Achromycin V Tetracycline Hydrochloride · Avet · 1957
Drugs in development for acne
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- ASC40Phase 32 trials
Ascletis Pharmaceuticals Co., Ltd. · Acne
- DenifanstatPhase 31 trial
Sagimet Biosciences Inc. · Acne Vulgaris
- DMT310Phase 31 trial
Dermata Therapeutics · Acne Vulgaris
- HB0043Phase 22 trials
Shanghai Huaota Biopharmaceutical Co., Ltd. · Acne Vulgaris, Hidradenitis Suppurativa
- AT-004Phase 21 trial
Arctic Therapeutics · Acne Vulgaris on the Face
- B244Phase 21 trial
AOBiome LLC · Acne Vulgaris
1 discontinued brand-name drugs whose label still names it
- Acticlate Cap Doxycycline Hyclate
More on acne: recruiting trials · published research
Related in dermatology: Rosacea
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.